A Phase Ib Study of OBT076 or OBT076 Followed by Balstilimab in Patients With Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (AdCC) of the Head and Neck (H&N)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Balstilimab (Primary) ; MEN 1309 (Primary)
Indications Adenoid cystic carcinoma; Endometrial cancer; Head and neck cancer; Ovarian cancer; Solid tumours; Tracheal neoplasms
Focus Therapeutic Use
Acronyms AdCC_2023-01
Sponsors Groupe Oncologie Radiotherapie Tete et Cou

25 Nov 2024 Status changed from suspended to completed.
11 Jul 2024 Status changed from recruiting to suspended due to toxicity.
18 Jan 2024 According to Oxford BioTherapeutics media release, the first patient has been dosed in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com